Fostamatinib clinical trials
Also written Tavalisse.
How each study uses fostamatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the fostamatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Apr 2018 · TAVALISSE · NDA 209299 (FDA, Drugs@FDA)
- European Union
- 9 Jan 2020 · Tavlesse · EMEA/H/C/005012 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
54 studies that test it; most in 2011 (8)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 6 |
| 2011 | 8 |
| 2012 | 6 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 37 · Other 17
AstraZeneca (21) · Rigel Pharmaceuticals (15) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Imperial College London (2) · Stefanie Sarantopoulos, MD, PhD. (2) · Kissei Pharmaceutical Co., Ltd. (1) · M.D. Anderson Cancer Center (1) · Sean Collins (1)
Often tested with
Tested in the same studies.
Ruxolitinib (2) · Talfirastide (1) · Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OH (1) · Simvastatin (1) · Pioglitazone (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test fostamatinib.
- May 2027Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell DiseasePhase 1 · National Heart, Lung, and Blood Institute (NHLBI)
- May 2027Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized AdultsPhase 2 · Inova Health Care Services
Studies
Open first, then newest update. How each study uses fostamatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 54
- Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific AntibodiesRecruitingPhase 1National Heart, Lung, and Blood Institute (NHLBI)NCT06948097Written as fostamatinibHow we know
- Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell DiseaseRecruitingPhase 1National Heart, Lung, and Blood Institute (NHLBI)NCT05904093Written as FostamatinibHow we know
- Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized AdultsNot yet recruitingPhase 2Inova Health Care ServicesNCT06564207Written as FostamatinibHow we know
- Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHDRecruitingPhase 1Stefanie Sarantopoulos, MD, PhD.NCT06233110Written as FostamatinibHow we know
- A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaEnrolling by invitationPhase 3Rigel PharmaceuticalsNCT04138927Written as Fostamatinib disodiumHow we know
- Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated CytopeniasTerminatedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT05502783Written as fostamatinibHow we know
- Inflammatory Signal Inhibitors for COVID-19 (MATIS)CompletedPhase 1/2Imperial College LondonNCT04581954Written as FostamatinibHow we know
- Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated CytopeniasWithdrawnPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT05509582Written as fostamatinibHow we know
- A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788CompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT04132050Written as R788How we know
- International Sites: Novel Experimental COVID-19 Therapies Affecting Host ResponseTerminatedPhase 2/3NEAT ID FoundationNCT05593770Written as FostamatinibHow we know
- Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy with Hypomethylating AgentsCompletedPhase 1M.D. Anderson Cancer CenterNCT05030675Written as FostamatinibHow we know
- Novel Experimental COVID-19 Therapies Affecting Host ResponseCompletedPhase 2/3Sean CollinsNCT04924660Written as FostamatinibHow we know
- Fostamatinib in the Treatment of Chronic Active Antibody Mediated RejectionActive, not recruitingPhase 1/2Imperial College LondonNCT03991780Written as FostamatinibHow we know
- Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian CancerCompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03246074Written as Fostamatinib 100 mg bid and PaclitaxelHow we know
- Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe ThrombocytopeniaTerminatedPhase 2Washington University School of MedicineNCT04543279Written as FostamatinibHow we know
- Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedPhase 3Rigel PharmaceuticalsNCT02077192Written as Fostamatinib DisodiumHow we know
- A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHACompletedPhase 3Rigel PharmaceuticalsNCT03764618Written as Fostamatinib disodiumHow we know
- Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell TransplantCompletedPhase 1Stefanie Sarantopoulos, MD, PhD.NCT02611063Written as fostamatinibHow we know
- Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis SuppurativaCompletedPhase 2Holdsworth House Medical PracticeNCT05040698Written as FostamatinibHow we know
- Fostamatinib for Hospitalized Adults With COVID-19CompletedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT04579393Written as fostamatinibHow we know
See all 54 studies that test fostamatinib →
Given beside what is tested · 1 — fostamatinib is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with fostamatinib
Codes
What other systems call fostamatinib · ClinicalTrials.gg INT005170
- MeSH (NLM) C523665fostamatinibOne source NLM
- UNII (FDA) SQ8A3S5101FOSTAMATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2044896One source FDA
- Wikidata Q5473550fostamatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95222FostamatinibOne source FDA
- DrugBank DB12010One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C523665 | fostamatinib | One source NLM |
| UNII (FDA) | SQ8A3S5101 | FOSTAMATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2044896 | — | One source FDA |
| Wikidata | Q5473550 | fostamatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95222 | Fostamatinib | One source FDA |
| DrugBank | DB12010 | — | One source Wikidata |
Also registered as fostamatinib disodium (UNII 86EEZ49YVB · RxNorm 2055929) and fostamatinib disodium anhydrous (UNII X9417132K8).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.